Q4 2019 13F Holders as of 31 Dec 2019
-
Type / Class
-
Equity / Common Stock, $0.0001 Par Value Per Share
-
Shares outstanding
-
107,800,271
-
Total 13F shares
-
38,034,445
-
Share change
-
-2,243,857
-
Total reported value
-
$1,304,492,153
-
Put/Call ratio
-
218%
-
Price per share
-
$34.31
-
Number of holders
-
133
-
Value change
-
-$41,694,110
-
Number of buys
-
60
-
Number of sells
-
68
Institutional Holders of Intra-Cellular Therapies, Inc. - Common Stock, $0.0001 Par Value Per Share (ITCI) as of Q4 2019
As of 31 Dec 2019,
Intra-Cellular Therapies, Inc. - Common Stock, $0.0001 Par Value Per Share (ITCI) was held by
133 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
38,034,445 shares.
The largest 10 holders included
FMR LLC, VANGUARD GROUP INC, BlackRock Inc., Bellevue Group AG, Consonance Capital Management LP, WASATCH ADVISORS INC, DIMENSIONAL FUND ADVISORS LP, PRICE T ROWE ASSOCIATES INC /MD/, STATE STREET CORP, and MORGAN STANLEY.
This page lists
133
institutional shareholders reporting positions in this security
for the Q4 2019 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.